Physician profile
Gehan P Devendra
NPI 1215015995
$6,169.30
in general payments reported to CMS, 2019-2025
20 companies · $3,717 in 2025
The $3,717 reported for 2025 was more than what 91% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $83.34 · 2021: $186 · 2022: $379 · 2023: $941 · 2024: $347 · 2025: $3,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,544 · Food and Beverage: $2,425 · Education: $36.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,543.86 |
| Food and Beverage | $2,425.41 |
| Education | $36.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,133.72 | 2024-2025 | Winrevair |
| Insmed, INC. | $655.90 | 2019-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $622.89 | 2019-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $296.51 | 2019-2022 | |
| United Therapeutics Corporation | $234.32 | 2021-2025 | Tyvaso |
| Glaxosmithkline, LLC. | $209.27 | 2020-2023 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $164.36 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.01 | 2019-2023 | |
| Mallinckrodt Enterprises LLC | $125.00 | 2019 | |
| Shionogi INC | $121.18 | 2025 | |
| Pharming Healthcare, INC. | $119.37 | 2024 | Joenja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.24 | 2022 | |
| Viatris Specialty LLC | $49.18 | 2025 | Yupelri |
| Abbvie INC. | $45.35 | 2021-2023 | Avycaz |
| Philips North America LLC | $39.90 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $33.39 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.52 | 2019 | |
| Sandoz INC. | $20.03 | 2025 | Treprostinil |
| Regeneron Healthcare Solutions, INC. | $17.13 | 2019 | |
| Allergan, INC. | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gehan Devendra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.